AMT

Across TCGA pan-cancer cohorts, AMT Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated AMT data layer compared with 23 for mass-spec protein and 8 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher AMT Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated AMT expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SKCM, TGCT, and BRCA are the cancer types where AMT Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	All	0.179	0.781	<.001	11	view →
TGCT	DFS	Median	II,III,IV	0.088	0.917	.010	6	view →
BRCA	DFS	Median	All	0.112	0.526	.005	6	view →
BLCA	DFS	Median	IV	0.025	0.476	<.001	3	view →
UCEC	DFS	Median	All	1.000	0.631	.039	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

AMT–SKCM (OS)

Open the SKCM breakdown →